The ledger
The numbers behind the news
Prices, dates and ratings from every story, kept in one place. Pick a section.
The price ledger tracks three monthly prices step by step: the US self-pay price of a Wegovy pen, the US self-pay price of a Zepbound vial at the lowest dose and the UK private list price of Mounjaro at the top dose. Each step carries the date it applied and links to the story that reported it. The other two sections list the dates coverage and rule changes take effect and rate every story for the five readers it reaches.
Price ledger
Zepbound vial, self-pay
Cash price for the 2.5 mg starting vial bought through LillyDirect. Shown per month, lowest dose.
| Date | Price | What changed | Story |
|---|---|---|---|
| 25 Feb 2025 | $349 | Price cut, higher doses added | Read |
| 27 Aug 2024 | $399 | Vials launch at 2.5 mg | Read |
Wegovy pen, self-pay
Cash price through Novo Nordisk’s own pharmacy channel, outside insurance. Shown per month, all doses.
| Date | Price | What changed | Story |
|---|---|---|---|
| 17 Nov 2025 | $349 | Cash price cut again | Read |
| 5 Mar 2025 | $499 | NovoCare Pharmacy opens | Read |
| 1 Jun 2024 | $1,349 | List price, no cash channel yet | — |
Mounjaro, top dose, private
Price the maker charges UK private suppliers for the highest-dose pen. Shown list price per month, 15 mg.
| Date | Price | What changed | Story |
|---|---|---|---|
| 1 Sep 2025 | £330 | List price rise takes effect | Read |
| 1 Feb 2024 | £122 | UK private launch price | — |
Self-pay and list prices as announced by the makers. Pharmacy retail prices and plan copays differ.
Takes effect
2024
-
27Aug
In force
On sale the same dayUS
Lilly starts selling Zepbound in vials for cash, at $399 for the starting dose -
1Oct
In force
Ban in forceAustralia
Australia ends the compounding of GLP-1 copies -
18Dec
In force
Deal closedGlobal
Novo takes over three Catalent fill plants to make more pens
2025
-
25Feb
In force
New prices on LillyDirectUS
Zepbound vials get cheaper and reach higher doses - 5Mar In force
-
19Mar
In force
Last day for large compoundersUS
A judge declines to stop the end of the tirzepatide shortage -
23Jun
In force
Partnership endedUS
Novo walks away from its Hims & Hers partnership after eight weeks -
23Jun
In force
Primary-care rollout beginsUK
Family doctors in England begin prescribing Mounjaro for weight loss -
1Jul
In force
Formulary change in forceUS
CVS Caremark picks Wegovy over Zepbound on its main drug lists -
1Sep
In force
New list prices applyUK
Lilly raises the UK private price of Mounjaro, up to almost three times for the top dose - 9Sep In force
- 17Nov In force
2026
-
1Jan
In force
Coverage for weight loss endsUS
California’s Medicaid program will stop paying for GLP-1s for weight loss -
1Jan
In force
The proposal would have started hereUS
Medicare will not cover weight-loss drugs in 2026 after all -
1Jul
In force
Medicare coverage planned from mid-2026US
A White House deal puts weight-loss drugs on a path into Medicare at $245 a month -
15Oct
In force
Gesy covers Mounjaro for adults with severe obesity and for type 2 diabetesCyprus
Mounjaro on Gesy covers severe obesity in Cyprus with weight loss targets and a two year limit -
29Oct
Coming
Eppe available by prescription at selected clinics in Korea, around this dateSouth Korea
Eppe obesity drug price in Korea starts near half of Mounjaro as Hanmi launches October 29
2027
-
6Jan
Coming
Administrative hearing on the summary suspension in ColumbusUS
Ohio Board of Pharmacy suspends a Sylvania med spa drug license over unapproved peptides -
31Dec
Coming
Medicare GLP-1 Bridge ends and its prior authorizations expireUS
Who qualifies for the Medicare $50 copay on Wegovy Zepbound and Foundayo